down arrow

Aethlon Medical, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00808Y4061
USD
4.03
-0.92 (-18.59%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.684.08

52 Week

3.4284.40
Valuation
Technical
Day's Volume

CASH

27.21 k

Shareholding (Dec 2024)

FII

1.71%

Held by 6 FIIs

DII

97.32%

Held by 1 DIIs

Promoter

0.00%

How big is Aethlon Medical, Inc.?

22-Jun-2025

As of Jun 18, Aethlon Medical, Inc. has a market capitalization of 3.56 million and reported net sales of 0.00 million with a net profit of -9.56 million over the last four quarters. Shareholder's funds were 5.77 million, and total assets were 8.25 million.

As of Jun 18, Aethlon Medical, Inc. has a market capitalization of 3.56 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a consolidated net profit of -9.56 million over the same period.<BR><BR>As of Mar 24, the company's shareholder's funds amounted to 5.77 million, while total assets were reported at 8.25 million.

Read More

What does Aethlon Medical, Inc. do?

22-Jun-2025

Aethlon Medical, Inc. is a micro-cap medical device company focused on developing devices for cancer and infectious diseases. As of December 2024, it has a market cap of $3.56 million and reported a net profit loss of $2 million.

Overview: <BR>Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease, and other life-threatening conditions, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -2 Million (Quarterly Results - Dec 2024) <BR>Market cap: USD 3.56 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.04 <BR>Return on Equity: -220.54% <BR>Price to Book: 0.82<BR><BR>Contact Details: <BR>Address: 9635 Granite Ridge Dr Ste 100, SAN DIEGO CA: 92123 <BR>Tel: 1 858 4597800 <BR>Website: https://www.aethlonmedical.com/

Read More

Who are in the management team of Aethlon Medical, Inc.?

22-Jun-2025

As of March 2022, the management team of Aethlon Medical, Inc. includes Mr. Edward Broenniman (Chairman of the Board), Ms. Sabrina Johnson (Independent Director), and Dr. Chetan Shah (Independent Director).

As of March 2022, the management team of Aethlon Medical, Inc. includes Mr. Edward Broenniman, who serves as the Chairman of the Board, Ms. Sabrina Johnson, an Independent Director, and Dr. Chetan Shah, also an Independent Director.

Read More

Is Aethlon Medical, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Aethlon Medical, Inc. is in a bearish trend, indicated by a bearish daily moving average and monthly Bollinger Band, despite some mildly bullish MACD signals, and has significantly underperformed the S&P 500 with a year-to-date return of -88.66%.

As of 8 September 2025, the technical trend for Aethlon Medical, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators driving this conclusion including a bearish daily moving average and a bearish monthly Bollinger Band. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall sentiment is dampened by the bearish Dow Theory and the lack of trend in the On-Balance Volume (OBV). <BR><BR>In terms of performance, Aethlon Medical has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -88.66% compared to the S&P 500's 12.22%, and a staggering 10-year return of -99.32% versus the S&P 500's 231.64%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.97

stock-summary
Return on Equity

-232.67%

stock-summary
Price to Book

0.51

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-70.15%
0%
-70.15%
6 Months
-85.61%
0%
-85.61%
1 Year
-87.17%
0%
-87.17%
2 Years
-97.6%
0%
-97.6%
3 Years
-98.81%
0%
-98.81%
4 Years
-99.76%
0%
-99.76%
5 Years
-99.72%
0%
-99.72%

Aethlon Medical, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Aethlon Medical, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Aethlon Medical, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators driving this conclusion including a bearish daily moving average and a bearish monthly Bollinger Band. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall sentiment is dampened by the bearish Dow Theory and the lack of trend in the On-Balance Volume (OBV). In terms of performance, Aethlon Medical has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -88.66% compared to the S&P 500's 12.22%, and a staggering 10-year return of -99.32% versus the S&P 500's 231.64%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-17.59%
EBIT Growth (5y)
-12.09%
EBIT to Interest (avg)
-9.18
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.98
Sales to Capital Employed (avg)
0.05
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.47%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.22
EV to EBIT
-0.08
EV to EBITDA
-0.08
EV to Capital Employed
-0.79
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-220.54%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 3 Schemes (0.97%)

Foreign Institutions

Held by 6 Foreign Institutions (1.71%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 71.43% vs -250.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.60",
          "val2": "-1.90",
          "chgp": "15.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-4.60",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.80",
          "val2": "-6.30",
          "chgp": "71.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs -100.00% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -9.84% vs -1.67% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.00",
          "val2": "-12.30",
          "chgp": "26.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.40",
          "val2": "-12.20",
          "chgp": "-9.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.60
-1.90
15.79%
Interest
0.00
0.00
Exceptional Items
0.00
-4.60
100.00%
Consolidate Net Profit
-1.80
-6.30
71.43%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 71.43% vs -250.00% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-9.00
-12.30
26.83%
Interest
0.00
0.00
Exceptional Items
-4.60
0.00
Consolidate Net Profit
-13.40
-12.20
-9.84%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 0.00% vs -100.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -9.84% vs -1.67% in Mar 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Aethlon Medical, Inc. stock-summary
stock-summary
Aethlon Medical, Inc.
Pharmaceuticals & Biotechnology
Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company's lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.
Company Coordinates stock-summary
Company Details
9635 Granite Ridge Dr Ste 100 , SAN DIEGO CA : 92123
stock-summary
Tel: 1 858 4597800
stock-summary
https://www.aethlonmedical.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."